share_log

Insider Buying: Eterna Therapeutics Inc. (NASDAQ:ERNA) Major Shareholder Buys $1,101,817.60 in Stock

Insider Buying: Eterna Therapeutics Inc. (NASDAQ:ERNA) Major Shareholder Buys $1,101,817.60 in Stock

内幕买盘:Eterna Therapeutics Inc.(纳斯达克股票代码:ERNA)主要股东购买1,101,817.60美元的股票
Financial News Live ·  2022/12/08 05:11

Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Rating) major shareholder John D. Halpern acquired 335,920 shares of the stock in a transaction on Friday, December 2nd. The stock was acquired at an average cost of $3.28 per share, for a total transaction of $1,101,817.60. Following the acquisition, the insider now directly owns 450,961 shares in the company, valued at approximately $1,479,152.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Eterna Therapeutics Inc.(纳斯达克股票代码:ERNA — Get Rating)主要股东约翰·哈尔珀恩在12月2日星期五的一笔交易中收购了该股335,920股。该股的平均收购成本为每股3.28美元,总交易额为1,101,817.60美元。收购后,该内部人士现在直接拥有该公司的450,961股股份,价值约为1,479,152.08美元。此次收购是在向美国证券交易委员会提交的一份文件中披露的,该文件可通过以下方式获取 美国证券交易委员会网站。拥有公司至少 10% 股份的主要股东必须向美国证券交易委员会披露其销售和购买情况。

Eterna Therapeutics Trading Up 4.7 %

Eterna Therapeutics 交易价格上涨

Shares of NASDAQ:ERNA opened at $4.67 on Thursday. Eterna Therapeutics Inc. has a 12 month low of $2.73 and a 12 month high of $127.60.

纳斯达克股票代码:ERNA的股价周四开盘价为4.67美元。Eterna Therapeutics Inc.创下12个月低点2.73美元,12个月高点为127.60美元。

Get
获取
Eterna Therapeutics
Eterna 疗法
alerts:
警报:

About Eterna Therapeutics

关于埃特纳疗法

(Get Rating)

(获取评分)

Brooklyn ImmunoTherapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.
Brooklyn ImmunoTherapeutics, Inc是一家临床阶段的生物制药公司,致力于开发治疗癌症患者的疗法。它的先进项目是 IRX-2,该项目正在对头颈部鳞状细胞癌患者进行 2b 期临床试验。该公司还使用基因编辑和细胞疗法技术开发疗法,用于治疗肿瘤学、血液疾病和单基因疾病。

Recommended Stories

推荐故事

  • Get a free copy of the StockNews.com research report on Eterna Therapeutics (ERNA)
  • Are Investors Hearing The End Of Spotify's Downtrend?
  • The Question of a Fed Pivot Isn't If, It's When, Here's Why
  • Top 10 Searched Stocks on MarketBeat All-Access
  • 3 Dividend Kings With Royally Good Upside
  • Institutions Sell The Rallies In Toll Brothers Stock
  • 免费获取 StockNews.com 关于 Eterna Therapeutics (ERNA) 的研究报告
  • 投资者在听见 Spotify 下跌趋势的结束吗?
  • 美联储转向的问题不在于是否,而是何时,这就是原因
  • MarketBeat All-Access 上搜索
  • 3 位股息之王,上行空间不错
  • 机构卖出 Toll Brothers 股票的涨势

Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Eterna Therapeutics 每日的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Eterna Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发